97726798 - ULTRAGENYX

Information

• Trademark
• 97726798

• Source

• Serial Number

  97726798

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 9 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments
  • 16 - Paper, cardboard and goods made from these materials, not included in other classes
  • 36 - Insurance
  • 41 - Education
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services
  • 45 - Legal services

• Filing Date

  December 21, 2022
  a year ago

• Transaction Date

  February 06, 2024
  3 months ago

• Status Date

  February 06, 2024
  3 months ago

• Published for Opposition Date

  December 12, 2023
  5 months ago

• Location Date

  February 06, 2024
  3 months ago

• Status Code

  688

• Current Location

  INTENT TO USE SECTION

  Employee Name

  HELLMAN, ELI J

• Attorney Docket Number

  315613-20000

  Attorney Name

  Anne H. Peck

  Law Office Assigned Location Code

  L20

• Owners

  • ULTRAGENYX PHARMACEUTICAL INC.

Case File Statements

• GS0411: education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of rare diseases and disorders; online journals, namely, blogs featuring information on rare diseases and disorders
• DM0000: The mark consists of the word "ultragenyx" in a lower-case stylized font.
• GS0091: downloadable software for creating, editing, uploading, downloading, accessing, viewing, posting, displaying, tagging, blogging, streaming, linking, annotating, indicating sentiment about, commenting on, embedding, transmitting, and providing electronic media information via computer, the internet and communication networks in the field of rare diseases and disorders; downloadable software for modifying and enabling transmission of images, audio, audio visual and video content and data in the field of rare diseases and disorders; downloadable computer software for use in inputting, gathering, monitoring, sharing, and analyzing patient data with respect to medical histories, health status and disease progression and treatment
• GS0051: Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, inflammatory, autoimmune, musculoskeletal, ophthalmologic, respiratory, osteopathic, oncologic, endocrine, orthopedic, metabolic, lipid-related, genetic, neuromuscular, autosomal, lysosomal storage, enzyme, hematologic and long-chain fatty acid oxidation disorders (LC-FAOD) diseases and disorders; chemical, biological, and biochemical preparations for use in gene delivery technology for medical use, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for use in in vivo therapeutic use in gene therapy
• GS0161: printed publications, namely, books, brochures, informational pamphlets, informational cards, and advertisements being signs and boards of paper in the field of rare diseases and disorders
• PM0001: ULTRA GENE
• GS0361: financial and insurance consultation services, namely, patient advisory, support and consultancy services regarding patient finances, insurance and access to medical treatment; providing financial and insurance information, namely, providing information and guidance in connection with health insurance benefit plans and other patient financial assistance resources; financial and insurance consultation services, namely, insurance and medical and pharmaceutical access consultation services, namely, assisting patients and their caregivers to identify the scope of coverage offered by patient medical and pharmaceutical insurance and to identify other financial assistance resources for payment of patient treatment; insurance consultation services, namely, assisting patients and their caregivers to obtain authorization and payment for medical and pharmaceutical costs
• CC0000: Color is not claimed as a feature of the mark.
• GS0011: Chemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids, including, coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for use in vitro laboratory use; chemical, biological, and biochemical preparations for use in the manufacture of pharmaceutical preparations
• GS0451: Licensing of intellectual property; online social networking services in the field of rare diseases and disorders
• GS0441: providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders; medical consulting services in the field of rare diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of rare diseases and disorders, and collecting data and information on rare diseases and disorders for screening, diagnosis and treatment purposes; medical information services in the nature of providing a database in the field of hypophosphatemia information based on collected patient data and information all for treatment and diagnostic purposes
• GS0421: Pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of rare diseases and disorders; medical and scientific research information in the field of rare diseases and disorders; computer services, namely, creating an on-line community for registered users to obtain feedback from their peers, interact with research data, and share data in the field of rare diseases and disorders; pharmaceutical research services, namely, recruitment of rare disease patients for panels such as pharmaceutical research panels; providing medical research and scientific research information in the field of hypophosphatemia

Case File Event Statements

• 2/6/2024 - 3 months ago

  14 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 12/12/2023 - 5 months ago

  13 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 12/12/2023 - 5 months ago

  12 - PUBLISHED FOR OPPOSITION Type: PUBO

• 11/22/2023 - 6 months ago

  11 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 11/6/2023 - 6 months ago

  10 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 11/3/2023 - 7 months ago

  9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/3/2023 - 7 months ago

  8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 11/3/2023 - 7 months ago

  7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 9/25/2023 - 8 months ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 9/25/2023 - 8 months ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 9/25/2023 - 8 months ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 9/21/2023 - 8 months ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 1/18/2023 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 12/24/2022 - a year ago

  1 - NEW APPLICATION ENTERED Type: NWAP